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Abstract. 
 
Enormous progress has been made in the development of antisense 
oligodeoxynucleotides (ODNs) as therapeutic agents inhibiting gene 
expression. Unfortunately, the therapeutical application of ODNs is still held 
back because of the low cellular uptake and the lack of specific transport 
into particular cells. In this paper, we report a drug-targeting system using 
somatostatin receptors (SSTRs) which are overexpressed in various tumors. 
Phosphorothioate ODNs were covalently linked to Tyr3- octreotate, an 
analogue of somatostatin. The peptide was assembled by solid-phase 
synthesis, oxidized to form the cyclic disulfide, and subsequently derivatized 
with a N-terminal maleimido functionality. 5’-Thiol derivatized 
phosphorothioate-ODNs directed against the protooncogene bcl-2 were 
conjugated to this maleimido-modified peptide. Binding studies revealed 
that the conjugates retain specific binding with nanomolar affinities to 
SSTRs (IC50-values between 1.83 and 2.52 nM). Furthermore, melting 
studies with complementary DNA revealed that the terminal conjugation of 
the ODNs did not significantly affect their hybridization affinity. 
 
INTRODUCTION 
 
Antisense therapy holds great promise for the treatment of gene-
related disorders. Still, the major obstacle for an efficient antisense therapy 
is the low internalization rate into target cells. Even though ODNs are large, 
negatively charged molecules, they are to some extent transported through 
the cellular membranes. This uptake is achieved by pinocytosis and 
processes which are known to be concentration and energy dependent. 
Depending on the ODN, the cell line and experimental conditions, the 
uptake rate ranges 1-20%.  
Numerous attempts have been made to increase the intracellular 
bioavailability and to enable specific internalization into selected cell types. 
A highly efficient and versatile system for uptake enhancement is 
encapsulation into liposomes. Within liposomes, ODNs are preserved from 
serum nuclease degradation. Taking advantage from various coating 
modifications which increase stability and uptake, liposomes have become 
valuable shuttles for ODNs (1). ODNs attached to hydrophobic moieties, 
such as lipids (2), cholesterol (3), or geraniol (4), show increased antisense 
effects. However, these effects have always been controversially discussed 
because of sequence unrelated effects and the lack of a plausible 
mechanism. Cellular internalization of cationic molecules by adsorptive 
endocytosis has been exploited by several procedures. For example, cellular 
import can be increased with ODN-polylysine complexes (5) or ODNs 
conjugated to avidin (6). Conjugation of PNA with a monoclonal antibody to 
the rat transferrin receptor enabled the transport through the blood brain 
barrier (7). This approach led to a 28-fold uptake rate as compared to the 
unmodified ODN analogue. The complexes formed when mixing ODNs with 
porphyrin possess enhanced stability and cellular delivery by an unknown 
mechanism (8). The ubiquitously expressed receptors for vitamin B6 can be 
addressed with ODNs conjugated to vitamin B6 (9). These conjugates were 
believed to be taken up by potocytosis. A unique targeting system for liver 
cells has been developed using the asialo-glycoprotein receptors (10). 
Residues of β-D-galactose within the asialo-glycoprotein mediate the 
selective uptake of the conjugated ODN into the liver. These findings should 
stimulate the search for selective targeting vectors which enable enhanced 
receptor-mediated delivery into other tissues. Peptides which bind to 
integrins (11) and the EGF-receptor family (12) represent examples of 
peptide vectors which have been employed for ODN-transport. These 
peptides bind to distinct receptors, which upon binding, mediate endocytosis 
of the peptide-ODN complex. Conjugates of ODNs with penetratins (13) or 
signal peptides (14, 15) acquire increased uptake rates due to the 
membrane translocation properties of these peptides. Hitherto no targeting 
system with selectivity for cancer cells and high capacity sufficient for 
antisense therapy has been found to be effective in vivo.  
Somatostatin is a cyclic tetradecapeptide found in the hypothalamus. 
It is an important regulating peptide which exerts inhibitory effects on the 
secretion of growth hormones. The SSTRs are known to be overexpressed 
by a variety of neoplastic tissues such as small cell lung cancers, breast 
tumors, brain tumors, and many other (mainly endocrine) tumors. 
Therefore, the membrane-associated SSTRs represent potential molecular 
targets for selective delivery into tumor cells. Because of the short biological 
half-live of the natural somatostatin (<3 min) in vivo, many analogues have 
been developed. Octreotide, a cyclic octapeptide with an improved 
specificity and a half-live of about 90 min (16) has become the most 
successful analogue. Recently, it has turned out that octreotate, the 
carboxylic acid derivative of octreotide, offers improved pharmacological 
properties and should therefore be an interesting alternative to octreotide 
(17). 
A large number of tumor types show aberrant gene expression of the 
protooncogene bcl-2. These abnormalities result in an overexpression of 
bcl-2 protein. This protein is known to inhibit apoptosis. Antisense ODNs 
have been used to inhibit bcl-2 expression in cellular studies (18). The 
model ODN used in the present studies is a 20-mer that corresponds to a 
selected part of the coding sequence within the genome of human bcl-2 
cDNA (19). Besides their high enzymatic stability, phosphorothioates have 
been shown to be highly potent in inhibiting bcl-2 expression (18). 
Therefore, the ODN conjugates were prepared as phosphorothioates. 
 Even though octreotate contains only eight residues, the synthesis is 
complicated by several structural features. In particular, cyclization of the 
disulfide bond does not converge with the introduction of amine- and 
thiolreactive groups necessary for conjugation. Hence, a synthetic protocol, 
which allows the solid-phase formation of the disulfide bond and subsequent 
attachment of the reactive group has been developed.  
In addition to the synthesis, we report herein data on binding 
specificity to the SSTRs and binding specificity to the corresponding ODNs. 
These experiments were performed to scrutinize whether the ODN-Tyr3-
octreotate conjugates fulfill the major prerequisites for receptor mediated 
uptake and antisense effect. 
 
 
EXPERIMENTAL PROCEDURES 
 
General. The peptides were analyzed and separated by liquid 
chromatography (HPLC) on a Gyncotech P-580 system (Germering, 
Germany) equipped with a variable SPD 6-A UV detector and a C-R5A 
integrator (both Shimadzu, Duisburg, Germany). The columns used were 
Nucleosil C18, 5 µm, 250 x 4 mm (Macherey & Nagel, Düren, Germany) and 
LiChrosorb RP-select B 10 µm, 250 x 10 mm (Merck, Darmstadt, Germany). 
The ODNs were purified on a Waters liquid chromatography system on PRP-
1 material 7 µm, 305 x 7 mm (Hamilton, Bondauz, Switzerland). UV 
measurements as well as the melting studies were performed with a 
computer interfaced Varian Cary 13 UV-vis spectrophotometer. Mass 
spectrometry analysis of the peptides and of the oligonucleotides was 
performed on a matrix-assisted laser desorption ionization time-of-flight 
mass spectrometer (MALDI-1, Kratos Instruments, England). 1H and 13C 
NMR spectra of compound 4 were recorded on a Bruker AM 250 
spectrometer and are expressed as δ units relative to CD3OD (δ) 49.3 for 
13C). The peptides were synthesized manually with an in-house 
manufactured SPPS reactor. The oligodeoxynucleotides were synthesized on 
an Applied Biosystems model 394 DNA synthesizer or on an PerSeptive 
Expedite 8900 synthesizer. Lyophilization was performed on a Christ 
(Osterode, Germany) R1-2 lyophilizator. Membrane-binding experiments 
were performed using an in-house manufactured filtration apparatus. 
 
Reagents. All standard synthesis reagents were purchased from 
Merck (Darmstadt, Germany). The chemicals for peptide synthesis were 
obtained from Novabiochem (La¨ufelfingen, Switzerland). N-Maleimido-6-
caproic acid, thallium(III)trifluoroacetate, and TIS were obtained from Fluka 
(Buchs, Switzerland). The chemicals for the oligonucleotide synthesis were 
obtained from Perkin- Elmer Applied Biosystems (Norwalk, Connecticut) or 
PerSeptive Biosystems (Hamburg, Germany). The sulfurization- reagent 
EDITH was from PerSeptive Biosystems. The thiol linker phosphoroamidite 
was purchased from Glen research (Sterling, Minnesota). Anhydrous 
solvents were obtained from Merck, PerSeptive Biosystems, and SDS 
(Peypin, France). NAP-10 gel filtration columns were from Pharmacia 
(Uppsala, Sweden). Protein was determined using the Bradford assay 
(Sigma). Water was purified by a Milli-Q water system from Millipore 
(Eschborn, Germany). Tyr3-octreotide was prepared by SPPS. Radioisotope 
Na125I was purchased from Amersham Pharmacia Biotech (Freiburg, 
Germany). [125I]Tyr3-octreotide was prepared by iodination of Tyr3-
octreotide using the chloramine-T method according to the method of 
Bakker et al. (20). The product was purified by HPLC and stored at -80 °C. 
The complementary unmodified phosphodiester and phosphorothioate ODNs 
for the melting temperature analysis 5’- GTT CTC CCA GCG TGT GCC AT-3’ 
(antisense) and 5’- ATG GCA CAC GCT GGG AGA AC-3’ (sense) were 
synthesized by standard procedures. 
 
Synthesis of the Maleimido-Peptide 4. The peptide was 
assembled by Fmoc chemistry on 1 g of Fmoc-Thr-(tBu)-Wang resin (0.61 
mmol/g). NR-Fmoc amino acids with the following side chain protecting 
groups were employed: Cys(Acm), Lys(Boc), Thr(tBu), D-Trp(Boc), and 
Tyr(tBu). All couplings were performed in DMF. The peptide chain was 
constructed manually according to a modified in situ neutralization cycle 
(21). Briefly, this cycle consisted of a 2-fold decoupling (1 and 5 min) with 
50% piperidine in DMF and 10 min coupling with 4 equiv of the Fmoc-amino 
acid (0.4 M in DMF, incubated for 5 min with 3.9 equiv of HBTU and 6 
equivDIPEA). After completion, the resin (1.75 g dry weight) was treated 
with piperidine in DMF to deprotect the terminal R-amino group of the 
peptide. An aliquot was cleaved and analyzed by HPLC indicating formation 
of 1 with a yield of >90%. A total of 200 mg of the resin-bound peptide 1 
was cyclized at room temperature with a 2-fold molar excess of thallium 
(III) trifluoroacetate in DMF. As determined by analysis of a small aliquot, 
formation of 2 was essentially complete within 1 h. After thorough washing, 
N-maleimido-6-caproic acid was coupled as described above, the resin was 
washed and dried under vacuum overnight. Cleavage was performed with 5 
mL of 37:1: 1:1 TFA/H2O/phenol/TIS for 2 h at room temperature. The 
resin was filtered and washed. The peptide was precipitated by the gradual 
addition of tert-butyl-methyl ether at 4 °C. Purification was accomplished by 
reversed phase HPLC on the RP-selectB column using a gradient of 20% B f 
50% B in 7.5 min and 50 f 100% B in 5 min (A ) H2O and B ) acetonitrile, 
both containing 0.1% TFA), flow rate ) 4 mL/min. Under these conditions, 
the peptide was eluted at 10.2 min. After lyophilization, 44 mg of 4 (43.6% 
overall yield) was obtained as a fluffy powder. The purified peptide was 
characterized by mass spectrometry. Anal. calcd for C59H75N11O15S2 [M + 
H]+: m/z 1243.4. Found: 1244.2. 13C NMR (CD3OD) ä ) 20.02 (q), 20.58 
(q), 22.89 (t), 26.28 (t), 27.14 (t), 27.70 (2 C) (t), 29.24 (t), 31.42 (t), 
36.75 (t), 38.40 (t), 39.34 (t), 40.19 (t), 40.65 (t), 46.45 (t), 46.52 (t), 
53.86 (d), 54.16 (d), 54.43 (d), 55.18 (d), 56.42 (d), 57.68 (d), 59.68 (d), 
60.55 (d), 68.55 (d), 69.09 (d), 110.41 (s), 112.33 (d), 116.23 (2 C) (d), 
128.66 (s), 128.91 (s), 129.34 (2 C) (d), 130.66 (2 C) (d), 131.54 (2 C) 
(d), 135.32 (2 C) (d), 137.99 (s), 138.56 (s), 157.35 (s), 171.26 (s), 
172.11 (s), 172.60 (2 C) (s), 172.74 (s), 173.26 (s), 173.57 (s), 174.20 
(s), 174.35 (s), 175.00 (s), 175.36 (s). 
 
Synthesis and Purification of the 5’-Thiol ODNs. The all-
phosphorothioate ODNs, 5’-GTTCTCCCAGCGTGTGCCAT- 3’ (antisense), 5’-
ATGGCACACGCTGGGAGAAC- 3’ (sense), and 5’-TACCGTGTGCGACCCTCTTG-
3’ (nonsense), were synthesized using β-cyanoethyl phosphoramidite 
chemistry at the 1 ímol scale. Acetylation was performed by 0.1 M acetic 
anhydride/tetrahydrofuran (THF) and 0.1 M imidazole/THF. Sulfurization 
was affected by using the EDITH reagent. The commercially available six-
carbon thiol linker phosphoroamidite (1-O-dimethoxytrityl-hexyl-disulfide-
1’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (Glen Research) was 
coupled to the 5’ end. The final coupling was followed by an acetonitrile 
wash. The resin was dried under a stream of argon and treated with 
concentrated ammonia containing 0.1 M DTT at 55 °C for 12 h to 
simultaneously affect deprotection of the thiol protection as well as cleavage 
from the resin (22). The resin was removed by filtration and rinsed with 
concentrated ammonia. Rotary evaporation of the resultant solution 
afforded a clear residue which was dissolved in sterile water. To remove 
excess DTT, the solution was passed through a NAP-10 gel filtration column. 
The fractions containing the ODN were immediately used for conjugation to 
the peptide. 
 
Synthesis of the Tyr3-Octreotate-Oligodeoxynucleotide 
Conjugates. The 5’-thiol-ODNs in eluent buffer were added to a solution of 
the maleimido-peptide 4 (5-fold excess) in aqueous 0.1 M TEAA, pH 6.5, 
containing 20% DMF. The pH was adjusted by adding 1 M TEAA, pH 6.5. 
The mixture was incubated at room temperature for 4 h after which time 
analytical HPLC indicated complete conjugation. Buffers A, 5% acetonitrile 
in 0.1 M TEAA, pH 6.5, and B, 70% acetonitrile in 0.1 M TEAA, pH 6.5, were 
employed for purification of the conjugates by RPHPLC. A linear gradient of 
0 to 100% B (2 mL/min) in 30 min was used. The conjugates eluting at 
22.3 min were collected and lyophilized. Yields were between 34 and 42% 
(based on the amount of the starting 5’-thiol-ODNs). The conjugates were 
characterized by MALDI-TOF analysis using 3-hydroxy-picolinic acid as 
matrix and a sample preparation essentially as described by Langley et al. 
(23): 5, m/z ) 7822.9 [M + H]+ (C258H335N79O120P20S23 calcd, 7819.96 
g/mol); 6, m/z ) 7936.8 [M + H]+ (C260H331N95O112P20S23, calcd, 7936.07 
g/mol); and 7, m/z) 7823.1 [M + H]+ (C258H335N79O120P20S23, calcd 7819.96 
g/mol). 
 
Melting Temperature Analysis of Hybridization. Melting studies 
were performed in stoppered quartz cells (1 cm path length) at 260 nm. 
Samples were prepared as 0.5 OD solutions of the two complementary 
oligomers in 1 mL of buffer. The buffer was 50 mM Tris/HCl, pH 7.5, 
containing 0.15 M NaCl. The melting curves were measured using a 
temperature gradient from 30 to 90 °C with a ramp rate of 0.5 °C/min. 
Prior to analysis, all samples were annealed by heating to 90 °C for 5 min 
and subsequently cooled slowly to room temperature. Analysis was carried 
out using the Varian thermal software. All Tm values were calculated from 
the first derivative of the melting curve and represent the average 
((standard deviation) of several analyses. Uncertainty in the Tm data is 
estimated at (0.5 °C based on repetitions of experiments. 
 
 
 
Scheme 1. Preparation of the Tyr3-Octreotate-ODN Conjugates 
 
SSTR Binding Assays. The concentration of the conjugates was 
determined using an estimated extinction coefficient. The extinction 
coefficient of the conjugate was assumed to be the sum of εODN and εpeptide: 
ε260nm) = Σ− [(nA x 15.4 + nC x 7.3 + nG x 11.7 + nT x 8.8) x 0.9] + (nTrp 
x 3.8 + nTyr x 0.5 + nPhe x 0.2). Using this equation, the following ε-
values were obtained: 5 ) 1.8 x 105, 6 ) 2.1 x 105, and 7 ) 1.8 x 105. For 
the binding assays, rat cortex membranes were resuspended at a protein 
concentration of 500 µg/mL in incubation buffer. Per assay, 100 µg of 
protein were employed. The incubation buffer was 10 mM HEPES, pH 7.6, 
containing 5% BSA fraction V, MgCl2 (10 mM), and bacitracin (20 íg/ mL). 
The cell membranes (200 µL) were mixed with 3 µL of incubation buffer 
containing increasing concentrations of the competitor (conjugates 5-7) 
(10-5-10-10 mol/ L). Approximately 20.000 cpm [125I]Tyr3-octreotide (ca. 20 
pM) in 70 µL of incubation buffer was added. After 1 h at room temperature, 
the incubation was stopped by quick filtration trough Whatman GF/B glass 
fiber filters prewetted with buffer containing 1% BSA. The filters were 
washed with ice-cold buffer (10 mM Tris, 150 mM NaCl), and the bound 
radioactivity was counted in a ç counter. Nonspecific binding, as determined 
by measuring binding in the presence of excess unlabeled octreotide (10-6 
mol/L), was approximately 10-20% of the total binding. Specific binding 
was defined as total binding minus nonspecific binding. Results are 
expressed as specific binding obtained from triplicate experiments. 
 
 
RESULTS 
 
Synthesis Strategy. To obtain targeted analogues of ODNs, 
conjugation to the SSTR affine Tyr3-octreotate was performed. Therefore, 
the peptide was functionalized with a maleimido group and the ODNs were 
modified with a sulfhydryl group. Upon reaction, a stable thioether bond is 
formed (Scheme 1).  
According to the Merrifield strategy, Tyr3-octreotate was synthesized 
on a solid support (Scheme 2). The tyrosine was introduced to enable 
radioactive labeling with iodine. Conjugation of the maleimido moiety to the 
peptide prohibited subsequent cyclization of the disulfide. Therefore, the 
success of this peptide synthesis was mainly depending on the elaboration 
of a protocol for on resin cyclization. 
Attempts to synthesize 2 using trityl protecting groups for cystein 
were impeded by incomplete couplings. This failure was probably due to the 
nonpolar aggregations of the lipophilic trityl groups. Using the smaller and 
polar Acm-protecting group, these problems could be circumvented. As 
determined by deprotection and HPLCanalysis of an aliquot, 1 was formed 
in SPPS in more than 90% yield. The deprotection/oxidation was attempted 
by different protocols [AgBF4 followed by DMSO/ HCl (24), I2 (25), and 
Tl(TFA)3 (26)]. The oxidation with Tl(TFA)3 using a 2-fold molar excess 
proved to produce the highest yields. The Trp-residue is known be 
susceptible to modifications during disulfide bond formations. Boc-
protection of the D-Trp-moiety was found to be inevitable to obtain 2 in 
high yields. 
 
 
 
Scheme 2. Preparation of the Maleimido Modified Tyr3-Octreotatea 
 
 
Edwards et al. (26) have observed severe problems with the on-resin 
cyclization of octreotide. To definitely confirm the integrity of 4, NMR 
analysis was performed. Both the 13C NMR spectrum as well as the 1H NMR 
spectrum (data not shown) were in accordance with the structure of 4, no 
byproducts could be observed. 
Upon oxidation, the 13C NMR resonance of the β-carbon atoms of 
cystein is shifted considerably downfield (e.g., from δ = 25.5 to δ = 38.9 for 
cystein in glutathione). Consequently, this chemical shift can be used to 
determine the oxidation status of disulfide bridged peptides. The 13C NMR 
signals of the two Cβ of cystein in compound 4 appeared at 46.4 and 46.5 
ppm, indicating formation of the disulfide bond. The chemical shift of 
carbons attached to disulfides is sensitive to changes in solvent and pH 
(26), to which this particular high shift can be attributed. 
Three 20-mer phosphorothioate ODN sequences complementary to 
bcl-2 (sense, antisense, and nonsense sequence) were synthesized on solid 
support. The six-carbon thiol linker (1-O-dimethoxytrityl-hexyl-disulfide-1’-
[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite was attached to the 5’ 
end. Cleavage was performed in aqueous NH3 containing 0.1 M DDT at 55 
°C overnight. Under these conditions, deprotection of the disulfide 
protection of the thiol-linker as well as cleavage from the resin was 
simultaneously achieved. Excess DTT was removed by gel filtration using 
double-distilled water as eluent. To prevent dimer-formation, the thiol ODNs 
were immediately conjugated to the maleimido-peptide. Failure to do that 
led to strongly varying coupling yields. In addition to the thiolated 
compound, the formation of an ODN byproduct which was not reactive to 
the maleimido peptide (probably the dimer) was observed and could not be 
suppressed. 
Purification of this ODN and incubation with DTT resulted in slow 
conversion to the reactive ODN. Attempts to substitute DTT by tris(2-
carboxyethyl)phosphine (27) led to complex mixtures containing little or no 
product. Large excess of DTT was found to afford the lowest rate of dimer 
formation, resulting in reliable good coupling yields.  
The conjugation reaction was performed on the basis of the synthesis 
technique previously described (28). Thus, the thiol modified ODNs were 
added to a solution of 4 in buffer containing DMF at pH 6.5. After 4 h, 
conjugation had reached completeness, as determined by HPLC. The 
chromatogram of the crude product mixture showed four peaks. These 
peaks corresponded to the truncated sequences and the unthiolated 
oligonucleotide at 16.8 min, the ODN-dimer byproduct at 19.2 min, the 
conjugate at 21.1 min, and excess maleimido peptide at 24.8 min (Figure 
1). Due to the significant differences in size and polarity, the conjugates 
could be easily separated by HPLC from the side products and excess 4. 
 
Melting Temperature Analysis. Melting temperature analysis was 
utilized to determine influences of the peptide moiety on the hybridization 
efficiency of the antisense ODN-peptide conjugate for its complementary 
strand. The dissociation of duplexes formed from equimolar concentrations 
of the ODN conjugates and an unmodified 20-mer ODN target was 
examined. Measurements were carried out in triplicate. The Tm of the parent 
unmodified 20-mer phosphodiester sequence was found to be 73.1 ( 0.2 °C. 
As compared to this, the Tm values of the conjugates 5 (65.0 ( 0.0 °C) and 
6 (63.8 ( 0.5 °C) appeared to be relatively low. The Tm of a 
phosphorothioate ODN is known to be decreased by about 0.5 °C per 
nucleotide as compared to a corresponding phosphodiester ODN (29). 
Therefore, the Tm curves were typical of those obtained with unmodified 
ODNs. To prove this, the analogous unmodified phosphorothioate ODNs 
were prepared. The resulting Tm values of the antisense (64.8 ( 0.5 °C) and 
the sense strand (66.2 ( 0.5 °C) confirmed that the prediction was correct. 
In Figure 2 the Tm curves of the duplex containing the conjugates 5, 6, the 
unmodified phosphorothioate ODNs, and the unmodified duplex are 
compared. These results indicate that the peptide moiety at the 5’-terminus 
of the 20-mer ODN does not interfere with the hybridization efficiency. 
 
Receptor Binding. To allow examination of competitive 
displacement, the concentrations of the conjugates were determined 
accurately using their extinction coefficients. Figure 3 shows the progressive 
displacement of [125I]Tyr3-octreotide from rat cortex membranes. The three 
conjugates investigated bound with high affinity in the low nanomolar 
range. The IC50 values of 5, 6, and 7 were 1.83 ( 0.17, 2.52 ( 0.43, and 
1.88 ( 0.47 nM, respectively. The similar affinities suggest that the 
sequence of the ODN does not significantly affect the receptor affinities. 
 
 
Scheme 3. Chemical Structure of the Tyr3-Octreotate-ODN Hybrid 
Molecules 
 
 
Figure 1. Reversed-phase HPLC chromatogram: Conjugation of a thiol-
modified oligonucleotide with maleimido-peptide 4. (A) Reaction mixture 
after 4 h. (I) Truncated sequences and the unthiolated oligonucleotide; (II) 
ODN-dimer byproduct, (III) conjugate, and (IV) excess maleimido peptide. 
(B) Purified conjugate 6. 
 
 
 
Figure 2. Melting curves of modified and unmodified 20-mer ODNs in 50 
mM Tris/HCl (pH 7.5) and 0.15 M NaCl. Duplexes prepared from 
complementary phosphorodiester strands with antisensebcl-2 
phosphorothioate (O), sense bcl-2 phosphorothioate (b), ODN conjugate 5 
(0), ODN conjugate 6 (9), and controlstrand antisense bcl-2 
phosphorodiester ([). For clarity only every tenth point is plotted. 
 
 
 
Figure 3. Displacement of [125I]Tyr3-octreotide from rat cortex membranes 
(triplicate measurements). The ordinate represents the percent specific 
binding which is total binding minus binding in the presence of the ODN 
conjugates 5 (0, straight line), 6 (O, dotted line), and 7 ([, dashed line). 
 
 
DISCUSSION 
 
The receptors of the hormone somatostatin are known to be 
overexpressed in various tumors. The ODN conjugates reported herein were 
designed to be targeted to these plasma membrane receptors. The SSTRs 
exhibit a high capacity as transport vehicles, e.g., for cargos as big as gold 
particles (30). Furthermore, they show high specificity, as known from 
octreoscan ([111In]-DTPA-D-Phe1-octreotide), a radiopharmaceutical for 
tumor scintigraphy (31). Therefore, analogues of somatostatin are ideal 
transport vehicles for the targeting of tumor cells. These assumptions have 
very recently been supported by the successful conjugation of cytotoxic 
compounds to somatostatin derivatives (32, 33). Using a postsynthetic 
approach, the conjugation of disulfide bridged peptides such as octreotide is 
complicated. This problem could be solved by coupling of thiol modified 
ODNs with a maleimido- derivatized peptide. To our knowledge this is the 
first report of a synthesis which enables the production of stable conjugates 
of ODNs with disulfide-bridged peptides.  
The major targets of conjugates targeted to SSTRs are the receptor 
subtypes 2 and 5, which are predominantly expressed in SSTR-positive 
tumors. The feasibility of the ODN conjugates to target SSTRs was 
demonstrated by receptor binding studies with rat cortex membranes, 
which mainly express SSTR2. The IC50 values of the conjugates were in the 
low nanomolar range, thus, demonstrating high affinity binding to SSTRs. 
Investigation of the hybridization properties revealed that the peptide at the 
5’-terminus of the 20-mer ODN does not influence the binding to 
complementary ODNs. These results provide a basis for the improvement of 
selective uptake of ODNs into tumors and therefore hold promise for further 
development and application of antisense therapy. Further development of 
these conjugates investigating their biodistribution, stability, and bioactivity 
in vivo is in progress. 
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